Navigation Links
Immunosyn Corporation to Present at FSX
Date:10/24/2007

LA JOLLA, Calif., Oct. 24 /PRNewswire-FirstCall/ -- Immunosyn Corporation's (OTC Bulletin Board: IMYN) CEO, Stephen Ferrone, will make a presentation to brokers and financial institutions at the Financial Services Exchange (FSX) Investment Conference at the Pointe South Mountain Resort in Phoenix, AZ on Thursday, October 25, 2007.

Immunosyn has obtained exclusive worldwide marketing, sales and distribution rights to SF-1019 from its largest shareholder, Argyll Biotechnologies, LLC. Research suggests that SF-1019 has analgesic properties with a perceived ability to substantially reduce the inflammation present in a number of clinical conditions including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS) and other auto-immune and neurological disorders. The company went public in January of this year and its stock will begin trading on Friday, October 26, 2007.

"Immunosyn is privileged to present to the elite group of brokers and dealers at FSX. We look forward to communicating our company's objectives and overview as well as to answering questions," noted Ferrone.

FSX is a premier investment conference organization attended by independent NASD broker/dealer firms. For more than 20 years, FSX has brought these firms together for the purpose of sharing information and showcasing investment opportunities.

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (OTC Bulletin Board: IMYN) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including auto-immune disorders such as Multiple Sclerosis (MS), neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS) and complications from Diabetic Mellitus such Diabetic Neuropathy (DN) and Diabetic Ulcers (DU).

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company's most recent public filings and Annual Report on Form 10-K for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.

FOR FURTHER INFORMATION, CONTACT: Bill Kraus/Lisa Baker/Devon Blaine

The Blaine Group

310/360-1499

310/360-1498 (FAX)

blaine@blainegroupinc.com


'/>"/>
SOURCE Immunosyn Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
11. Wisconsin firms to present at Cleantech venture capital event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 25, 2017 , ... ... full process behind each occurrence. Live cell imaging using fluorescence microscopy is the ... use of automated fluorescence microscopy methods will be discussed, from small animal models ...
(Date:5/24/2017)... ... May 24, 2017 , ... Today, the South Davis ... Advanced Biological Nutrient Recovery (ABNRâ„¢) technology at its 4,000,000 gallon per day South ... to sustainably meet current and future nutrient discharge regulations. The ABNR platform, which ...
(Date:5/24/2017)... 2017 (PRWEB) , ... May 24, 2017 , ... ... Medical systems are increasingly being developed with Wi-Fi connectivity to reduce the amount ... from room to room. In addition, compact mobile devices including infusion pumps, heart ...
(Date:5/23/2017)... Westminster, Colorado (PRWEB) , ... May 23, 2017 , ... ... amaranth as the most troublesome and difficult to control weed in 12 categories of ... found. , Almost 200 weed scientists across the U.S. and Canada participated in the ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
Breaking Biology News(10 mins):